These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11738740)

  • 1. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H; Collins WE; Saul A; Stowers AW
    Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
    Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
    Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
    Hisaeda H; Stowers AW; Tsuboi T; Collins WE; Sattabongkot JS; Suwanabun N; Torii M; Kaslow DC
    Infect Immun; 2000 Dec; 68(12):6618-23. PubMed ID: 11083773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic diversity and natural selection of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax Myanmar isolates.
    Lê HG; Kang JM; Jun H; Lee J; Moe M; Thái TL; Lin K; Myint MK; Yoo WG; Sohn WM; Kim TS; Na BK
    Acta Trop; 2019 Oct; 198():105104. PubMed ID: 31336059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China.
    Feng H; Zheng L; Zhu X; Wang G; Pan Y; Li Y; Yang Y; Lin Y; Cui L; Cao Y
    Parasit Vectors; 2011 Nov; 4():224. PubMed ID: 22117620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
    González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
    Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China.
    Wang S; Tian P; Li S; Liu H; Guo X; Huang F
    BMC Infect Dis; 2022 Dec; 22(1):944. PubMed ID: 36527077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multi-Stage
    McCaffery JN; Fonseca JA; Singh B; Cabrera-Mora M; Bohannon C; Jacob J; Arévalo-Herrera M; Moreno A
    Front Cell Infect Microbiol; 2019; 9():135. PubMed ID: 31119106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M; Iyori M; Blagborough AM; Fukumoto S; Funatsu T; Sinden RE; Yoshida S
    Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission-blocking vaccine of vivax malaria.
    Tsuboi T; Tachibana M; Kaneko O; Torii M
    Parasitol Int; 2003 Mar; 52(1):1-11. PubMed ID: 12543142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M; Solarte Y; Yasnot MF; Castellanos A; Rincón A; Saul A; Mu J; Long C; Miller L; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):32-7. PubMed ID: 16291764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
    Arakawa T; Tsuboi T; Kishimoto A; Sattabongkot J; Suwanabun N; Rungruang T; Matsumoto Y; Tsuji N; Hisaeda H; Stowers A; Shimabukuro I; Sato Y; Torii M
    Vaccine; 2003 Jul; 21(23):3143-8. PubMed ID: 12804841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.